ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1581

Neutrophil to Lymphocyte Ratio as a Predictor of Immune-Related Adverse Events in CTLA-4 Treated Patients: A Retrospective Review

Michael Cunningham1, Carolina Alvarez2, Shruti Saxena Beem3, Todd Schwartz4 and Rumey Ishizawar5, 1UNC Hospitals, Durham, NC, 2University of North Carolina at Chapel Hill Thurston Arthritis Research Center, Miami, FL, 3University of North Carolina at Chapel Hill, Chapel Hill, 4University of North Carolina-Chapel Hill, Chapel Hill, NC, 5University of North Carolina at Chapel Hill, Chapel Hill, NC

Meeting: ACR Convergence 2020

Keywords: Biomarkers, Drug toxicity, prognostic factors, risk factors, T-Lymphocyte

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Monday, November 9, 2020

Session Title: Immunological Complications of Therapy Poster

Session Type: Poster Session D

Session Time: 9:00AM-11:00AM

Background/Purpose: Immune checkpoint inhibitors (ICIs) target checkpoint proteins PD-1/PD-L1 and CTLA-4 to activate and enhance the cytotoxic effects of T lymphocytes against tumor cells [1-2]. This systemic effect disrupts immune homeostasis and can result in immune-related adverse events (irAEs) affecting a wide variety of organs, including rheumatic presentations. Interestingly, irAEs are also reflective of anti-tumor efficacy [3].

There are currently no biomarkers that predict impending irAEs. Several studies demonstrated an association between low neutrophil-to-lymphocyte ratio (NLR) and the risk of irAEs in patients treated with PD-1/PD-L1 blockade (Table 1). To date, the literature is limited on whether NLR may serve as a marker for irAEs in patients undergoing CTLA-4 blockade. As CTLA4 blockade affects a separate and distinct checkpoint pathway, we sought to understand the utility of NLR in this treatment group.

Methods: Under IRB approval, we conducted a retrospective electronic medical record review of oncology patients treated with ipilimumab (anti-CTLA4) at UNC Chapel Hill from 1/2004 to 7/2017. NLR was calculated from CBCs prior to initiation of ICI and compared against irAE type and incidence using logistic regression models to obtain odds ratios adjusted for age, sex, and ICI therapy type.

Results: 112 patients received ipilimumab (35.7% monotherapy with 64.3% in combination with other ICIs) and irAEs occurred in 72.3% of patients (Table 2). Lower NLR was shown to be associated with an increased risk of irAEs of any severity in patients treated with ipilimumab (Table 3). When stratifying irAEs by organ system, there was no statistically significant effect found. Despite this, the data suggest an association of NLR< 5 with rheumatologic irAEs. In addition, we noted an association of low NLR with dermatologic irAEs among women. While an exploratory endpoint, this difference between women and men is an intriguing finding not previously reported.

Conclusion: Our data investigating low NLR as a predictor for irAEs in CTLA-4 treated patients shows a similar association to that reported with PD-1 blockade. Furthermore, the effect size in our population is similar to previously published data with PD-1 blockade [4-7], suggesting this effect is not unique to cancer type or ICI type. The statistical significance was lost when stratified by organ system, suggesting a lack of power. Also of note is the difference in effect size based on NLR cut off value. To date, there is no standard value. While the data suggests NLR may be a predictor for irAE, it also encourages further investigation into organ specific irAEs, sex differences, and setting a standard for NLR cut off.


Disclosure: M. Cunningham, None; C. Alvarez, None; S. Saxena Beem, None; T. Schwartz, None; R. Ishizawar, None.

To cite this abstract in AMA style:

Cunningham M, Alvarez C, Saxena Beem S, Schwartz T, Ishizawar R. Neutrophil to Lymphocyte Ratio as a Predictor of Immune-Related Adverse Events in CTLA-4 Treated Patients: A Retrospective Review [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/neutrophil-to-lymphocyte-ratio-as-a-predictor-of-immune-related-adverse-events-in-ctla-4-treated-patients-a-retrospective-review/. Accessed February 28, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/neutrophil-to-lymphocyte-ratio-as-a-predictor-of-immune-related-adverse-events-in-ctla-4-treated-patients-a-retrospective-review/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.